Evidence map›Paper›PMID 29136405›Full record

Observational studyBritish journal of cancer2018

Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006-2014).

Benjamin Daniels, Belinda E Kiely, Nehmat Houssami, Sarah J Lord, Timothy Dobbins, Christine Y Lu, Robyn L Ward, Sallie-Anne Pearson

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in British journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Benjamin DanielsMedicines Policy Research Unit, Centre for Big Data Research in Health, University of New South Wales, Sydney, NSW 2052, Australia.
Belinda E KielyNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW 2050, Australia.
Nehmat HoussamiSydney School of Public Health, Sydney Medical School, University of Sydney, Sydney, NSW 2050, Australia.
Sarah J LordNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW 2050, Australia.
Timothy DobbinsNational Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW 2052, Australia.
Christine Y LuDepartment of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA 02215, USA.
Robyn L WardUniversity of Queensland, Brisbane QLD 4072, Australia.
Sallie-Anne PearsonMedicines Policy Research Unit, Centre for Big Data Research in Health, University of New South Wales, Sydney, NSW 2052, Australia.
UNSW Sydney · AUUniversity of Sydney · AUHarvard Pilgrim Health Care · USNational Health and Medical Research Council · AUUniversity of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients treated with (neo)adjuvant trastuzumab who relapse and receive trastuzumab for metastatic breast cancer (MBC) are a growing population with little outcome data given their exclusion from most clinical trials. We aim to estimate survival outcomes for this trastuzumab 'pre-treated' population.

methodsPopulation-based study of Australian women receiving trastuzumab for HER2-positive MBC between 2006 and 2014, who also received (neo)adjuvant trastuzumab. We used Kaplan-Meier methods to estimate the following: overall survival (OS) from initiation of trastuzumab for MBC; duration of trastuzumab for MBC; and time from last (neo)adjuvant trastuzumab to first trastuzumab for MBC.

resultsOf 3199 patients dispensed trastuzumab for MBC, 634 (20%) had received (neo)adjuvant traztuzumab. Pre-treated patients had a median (interquartile range) OS of 21.8 months (10.9-51.6), trastuzumab duration of 12.8 months (4.7-17.5), and time from last (neo)adjuvant trastuzumab to first trastuzumab for MBC of 15.6 months (6.5-28.6). Median OS for patients initiating trastuzumab <12 months and ⩾12 months from their last (neo)adjuvant trastuzumab were 17.1 months and 24.8 months, respectively.

conclusionsPatients starting trastuzumab for MBC following (neo)adjuvant trastuzumab had a median treatment duration of 1 year and OS of almost 2 years. These data help inform clinical practice and service planning for this under-researched population.

Indexed as

AgedAntineoplastic Agents, ImmunologicalAustraliaBreast NeoplasmsChemotherapy, AdjuvantErb-b2 Receptor Tyrosine KinasesFemaleHumansKaplan-Meier EstimateMiddle AgedNeoadjuvant TherapyNeoplasm MetastasisSurvival RateTime FactorsTrastuzumabAntineoplastic Agents, ImmunologicalERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesTrastuzumab

Identifiers

PMID29136405
PMCPMC5808025
OpenAlexW2768165937

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.